CoChat

Translating dosages from animal models to human clinical trials—revisiting body surface area scaling

Blanchard, Otis L., Smoliga, James M. · 2015 · The FASEB Journal

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Body surface area (BSA) scaling has been used for prescribing individualized dosages of various drugs and has also been recommended by the U.S. Food and Drug Administration as one method for using data from animal model species to establish safe starting dosages for first‐in‐human clinical trials. Although BSA conversion equations have been used in certain clinical applications for decades, recent recommendations to use BSA to derive interspecies equivalents for therapeutic dosages of drug and natural products are inappropriate. A thorough review of the literature reveals that BSA conversions are based on antiquated science and have little justification in current translational medicine compared to more advanced allometric and physiologically based pharmacokinetic modeling. Misunderstood and misinterpreted use of BSA conversions may have disastrous consequences, including underdosing leading to abandonment of potentially efficacious investigational drugs, and unexpected deadly adverse events. We aim to demonstrate that recent recommendations for BSA are not appropriate for animal‐to‐human dosage conversions and use pharmacokinetic data from resveratrol studies to demonstrate how confusion between the “human equivalent dose” and “pharmacologically active dose” can lead to inappropriate dose recommendations. To optimize drug development, future recommendations for interspecies scaling must be scientifically justified using physiologic, pharmacokinetic, and toxicology data rather than simple BSA conversion.—Blanchard, O. L., Smoliga, J. M. Translating dosages from animal models to human clinical trials—revisiting body surface area scaling. FASEB J. 29, 1629‐1634 (2015). www.fasebj.org

Overview

Integrity signals

Registry

Crossref · 10.1096/fj.14-269043

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 62 references

Research works printed but not linked: 4

  1. Center for Drug Evaluation and Research, 2002, Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers, Draft Guidance
  2. Rubner M., 1883, Über den einfluss der körpergrösse auf stoff- und kraftwechsel, Zeit. Biol., 19, 536
  3. Center for Drug Evaluation and Research, 2005, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
  4. Mahmood I., 2005, Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling

Cited by

See all 183

Metadata

Authors
Blanchard, O. L., & Smoliga, J. M.
Affiliations
  • Wilmore Labs Limited Liability Company San Antonio Texas USA
  • High Point University (US)
Corresponding author
Smoliga, James M.
Venue
The FASEB Journal
Publisher
Wiley
Published
2015-02-05
Volume
29
Issue
5
Pages
1629-1634
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2032445654
Cited by
183
References
61
Citations by year
2026: 23 · 2025: 27 · 2024: 16 · 2023: 14 · 2022: 22 · 2021: 22 · 2020: 14 · 2019: 13 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 6
FWCI
2.72
Type
journal article
Language
en
Open access
closed
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
interspecies scaling, resveratrol, human equivalent dose, allometric scaling, physiologically based pharmacokinetic modeling, drug dosing, translational medicine, adverse drug reactions
MeSH terms
Animals, Body Surface Area, Clinical Trials as Topic, Dose-Response Relationship, Drug, Humans, Species Specificity, Therapeutic Equivalency, Tissue Distribution, Drugs, Investigational, Models, Animal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Translating dosages from animal models to human clinical trials—revisiting body surface area scaling. https://app.cochat.ai/papers/10.1096/fj.14-269043
The paper
Blanchard, O. L., & Smoliga, J. M. (2015). Translating dosages from animal models to human clinical trials—revisiting body surface area scaling. The FASEB Journal. https://doi.org/10.1096/fj.14-269043

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.